3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
13
Advanced Breast Cancer
2
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Endometrial Neoplasms
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
exemestane
2
Tamoxifen
2
Letrozole
2
Immunotherapy
2
Anastrozole
2
ribociclib
1
elacestrant
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
abemaciclib
1
Taxes
1
Standard of Care
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Practice Guidelines as Topic
1
Neoadjuvant Therapy
1
Methods
1
Mental Status and Dementia Tests
1
Leuprolide
1
Interviews as Topic
1
Goserelin
1
Genetic Testing
1
Genetic Counseling
1
Educational Status
1
Early Intervention, Educational
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms, Male
×
elacestrant
×
90 days
×
Clear all
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled